Big Pharma Split Corp Class A (PRM) — Cash Flow Reinvestment Rate
Big Pharma Split Corp Class A (PRM) has a Cash Flow Reinvestment Rate of 0.00x as of September 2023, reinvesting CA$0.00 (capex CA$0.00 ) from operating cash flow of CA$644.28K. Explore PRM capex to operating cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Big Pharma Split Corp Class A Cash Flow Reinvestment Rate (2018–2023)
Historical reinvestment intensity for Big Pharma Split Corp Class A across 5 annual periods. Also explore Big Pharma Split Corp Class A asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Big Pharma Split Corp Class A (2018–2023)
Year-by-year capital reinvestment analysis for Big Pharma Split Corp Class A. For live market cap and broader valuation context, see Big Pharma Split Corp Class A (PRM) market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (CAD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2023 | 0.00x | CA$3.00 | CA$11.86 Million | CA$3.00 | — |
| 2022 | 0.00x | CA$0.00 | CA$1.13 Million | CA$0.00 | ▼ -100.0% |
| 2020 | 0.00x | CA$3.00 | CA$4.35 Million | CA$3.00 | — |
| 2019 | 0.00x | CA$0.00 | CA$8.68 Million | CA$0.00 | — |
| 2018 | 0.00x | CA$0.00 | CA$1.27 Million | CA$0.00 | — |